Positive News SentimentPositive NewsNASDAQ:ACRV Acrivon Therapeutics (ACRV) Stock Price, News & Analysis $4.92 -0.06 (-1.20%) (As of 12/29/2023 ET) Add Compare Share Share Today's Range$4.89▼$5.0550-Day Range$3.63▼$5.7552-Week Range$3.41▼$25.47Volume22,098 shsAverage Volume38,807 shsMarket Capitalization$109.19 millionP/E RatioN/ADividend YieldN/APrice Target$23.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Acrivon Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside377.6% Upside$23.50 Price TargetShort InterestBearish2.47% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.63) to ($2.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.97 out of 5 starsMedical Sector642nd out of 950 stocksPharmaceutical Preparations Industry311th out of 442 stocks 3.5 Analyst's Opinion Consensus RatingAcrivon Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.50, Acrivon Therapeutics has a forecasted upside of 377.6% from its current price of $4.92.Amount of Analyst CoverageAcrivon Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted2.47% of the float of Acrivon Therapeutics has been sold short.Short Interest Ratio / Days to CoverAcrivon Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Acrivon Therapeutics has recently increased by 3.56%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAcrivon Therapeutics does not currently pay a dividend.Dividend GrowthAcrivon Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACRV. Previous Next 3.3 News and Social Media Coverage News SentimentAcrivon Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Acrivon Therapeutics this week, compared to 1 article on an average week.Search Interest3 people have searched for ACRV on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Acrivon Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acrivon Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.30% of the stock of Acrivon Therapeutics is held by insiders.Percentage Held by Institutions68.54% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Acrivon Therapeutics are expected to decrease in the coming year, from ($2.63) to ($2.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acrivon Therapeutics is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acrivon Therapeutics is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcrivon Therapeutics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Acrivon Therapeutics Stock (NASDAQ:ACRV)Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.Read More ACRV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACRV Stock News HeadlinesDecember 5, 2023 | msn.comTravere Therapeutics, Replimune among healthcare moversDecember 1, 2023 | msn.comAcrivon Therapeutics files for $300M mixed shelfDecember 31, 2023 | MarketBeat Internal (Ad)MarketBeat All Access New Year's Sale - Just $1.00Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.November 28, 2023 | markets.businessinsider.comAcrivon Announces Breakthrough Device Designation For ACR-368 OncoSignature AssayNovember 28, 2023 | marketwatch.comAcrivon Therapeutics Gets FDA's Breakthrough Designation for Cancer AssayNovember 28, 2023 | markets.businessinsider.comAcrivon Gets FDA's Breakthrough Device Designation For ACR-368 OncoSignature AssayNovember 11, 2023 | benzinga.comAcrivon Therapeutics Stock (NASDAQ:ACRV), Analyst Ratings, Price Targets, PredictionsNovember 10, 2023 | markets.businessinsider.comAnalyst Ratings for Acrivon TherapeuticsDecember 31, 2023 | MarketBeat Internal (Ad)MarketBeat All Access New Year's Sale - Just $1.00Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.November 10, 2023 | markets.businessinsider.comPromising Future for Acrivon Therapeutics: Buy Rating Justified by Clinical Success and Expanding Market OpportunitiesNovember 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Acrivon Therapeutics, Inc. (ACRV)November 9, 2023 | msn.comAcrivon Therapeutics GAAP EPS of -$0.66 beats by $0.04November 9, 2023 | benzinga.comRecap: Acrivon Therapeutics Q3 EarningsOctober 16, 2023 | finance.yahoo.comAcrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsOctober 14, 2023 | finance.yahoo.comAcrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth PlansOctober 5, 2023 | markets.businessinsider.comAnalyst Expectations for Acrivon Therapeutics's FutureOctober 5, 2023 | msn.comMaxim Group Initiates Coverage of Acrivon Therapeutics (ACRV) with Buy RecommendationSeptember 29, 2023 | finanznachrichten.deAcrivon Therapeutics, Inc: Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 19, 2023 | finance.yahoo.comAcrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsSeptember 5, 2023 | finance.yahoo.comAcrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical StudiesAugust 30, 2023 | finance.yahoo.comAcrivon Therapeutics to Participate in Two Investor Conferences in SeptemberAugust 18, 2023 | msn.comJonesTrading Initiates Coverage of Acrivon Therapeutics (ACRV) with Buy RecommendationAugust 17, 2023 | finance.yahoo.comAcrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 11, 2023 | finanznachrichten.deAcrivon Therapeutics, Inc: Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business HighlightsAugust 11, 2023 | finance.yahoo.comAcrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business HighlightsJuly 20, 2023 | finance.yahoo.comAcrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate AffairsJune 22, 2023 | finance.yahoo.comAcrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of DirectorsSee More Headlines Receive ACRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/31/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACRV CUSIPN/A CIK1781174 Webwww.acrivon.com Phone617-207-8979FaxN/AEmployees56Year FoundedN/APrice Target and Rating Average Stock Price Target$23.50 High Stock Price Target$26.00 Low Stock Price Target$20.00 Potential Upside/Downside+377.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.39% Return on Assets-30.23% Debt Debt-to-Equity RatioN/A Current Ratio15.54 Quick Ratio15.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.16 per share Price / Book0.60Miscellaneous Outstanding Shares22,194,000Free Float20,574,000Market Cap$109.19 million OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Peter Blume-Jensen M.D. (Age 60)Ph.D., Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer Comp: $1.01MMs. Kristina Masson M.B.A. (Age 42)Ph.D., Co-Founder, Executive VP of Business Operations, Site Head, Treasurer, Secretary & Director Mr. Rasmus Holm-Jorgensen (Age 52)Chief Financial Officer Comp: $1MDr. Eric J. Devroe Ph.D. (Age 45)Chief Operating Officer Comp: $614.78kMs. Katharine Peterson CPAVice President of Finance & AccountingDr. Adam D. Levy M.B.A.Ph.D., Senior VP and Head of Investor Relations & Corporate AffairsMr. Bruce CloseVice President of Quality & ComplianceMs. Mary-Alice Miller J.D. (Age 49)General Counsel Ms. Parvin MiahVP & Head of Human ResourcesDr. Erick Gamelin M.D. (Age 65)Ph.D., Chief Medical Officer Comp: $480.72kMore ExecutivesKey CompetitorsOrganigramNASDAQ:OGIAssertioNASDAQ:ASRTDiaMedica TherapeuticsNASDAQ:DMACIO BiotechNASDAQ:IOBTKinnate BiopharmaNASDAQ:KNTEView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 65,132 shares on 12/18/2023Ownership: 2.111%Federated Hermes Inc.Sold 78,036 shares on 11/13/2023Ownership: 1.020%Northern Trust CorpBought 4,044 shares on 11/13/2023Ownership: 0.328%Charles Schwab Investment Management Inc.Bought 6,703 shares on 11/8/2023Ownership: 0.307%Ltd ChioneSold 16 sharesTotal: $206.88 ($12.93/share)View All Insider TransactionsView All Institutional Transactions ACRV Stock Analysis - Frequently Asked Questions Should I buy or sell Acrivon Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acrivon Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACRV shares. View ACRV analyst ratings or view top-rated stocks. What is Acrivon Therapeutics' stock price target for 2024? 6 brokers have issued 12 month price targets for Acrivon Therapeutics' stock. Their ACRV share price targets range from $20.00 to $26.00. On average, they predict the company's stock price to reach $23.50 in the next year. This suggests a possible upside of 377.6% from the stock's current price. View analysts price targets for ACRV or view top-rated stocks among Wall Street analysts. How have ACRV shares performed in 2023? Acrivon Therapeutics' stock was trading at $11.52 on January 1st, 2023. Since then, ACRV stock has decreased by 57.3% and is now trading at $4.92. View the best growth stocks for 2023 here. When is Acrivon Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our ACRV earnings forecast. How were Acrivon Therapeutics' earnings last quarter? Acrivon Therapeutics, Inc. (NASDAQ:ACRV) posted its earnings results on Thursday, November, 9th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.06. What ETF holds Acrivon Therapeutics' stock ? Range Cancer Therapeutics ETF holds 10,409 shares of ACRV stock, representing 1.23% of its portfolio. When did Acrivon Therapeutics IPO? (ACRV) raised $100 million in an initial public offering (IPO) on Tuesday, November 15th 2022. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO. How do I buy shares of Acrivon Therapeutics? Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACRV) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.